Grifols

Grifols, S.A.

Type	Sociedad Anónima
Traded as	BMAD: GRF NASDAQ: GRFS
Industry	Pharmaceuticals, chemicals
Founded	1940
Headquarters	Barcelona, Catalonia (Spain)
Key people	Víctor Grifols (Chairman and CEO)
Products	Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals
Revenue	€3,934.6 million (2015) €3,355.4 million (2014)
Operating income	€970.4 million (2015) €857.7 million (2014)
Profit	€532.1 million (2015) €470.3 million (2014)
Total assets	€9,601.7 million (2015) €8,449.7 million (2014)
Total equity	€3,301.4 million (2015) €2,662.9 million (2014)
Number of employees	13,731 (2015, average) 12,938 (2014, average)
Website	www.grifols.com

Grifols, S.A. (Catalan: [ɡɾiˈfɔɫs]) is a Spanish multinational pharmaceutical and chemical company. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments and reagents for clinical testing laboratories.

Grifols is the major world supplier of IVIG, albumin, Factor VIII and other plasma-derived products.

In 2007 the company had 3.6 million litres per year of blood fractionation capacity from three plants, one at Parets del Vallès near Barcelona in Spain (2.1 million litres per year), another in Los Angeles (1.5 million litres but being expanded to 2.2 million litres), and a site in Clayton, NC. In the United States the company owns 153 plasmapheresis centres, where it collects around 5.8 million litres of plasma per year.

Grifols was listed on the in May 2006. The stock became part of the IBEX 35 index in January 2008.

Grifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr José A. Grifols Roig, a hematologist and scientist. Dr Grifols was the first researcher to publish the plasmapheresis procedure in 1951. The company introduced its liquid IVIG product into the European market in the mid-1990s.

Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A. In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic (US subsidiary of Mitsubishi Pharma) as the basis of its American expansion. On May 17, 2006, Grifols securities were listed on Spain’s Mercado Continuo.